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The interaction of two glycoproteins, gp120, the major envelope protein ofthe
human immunodeficiency virus (HIV), and CD4, a 55-kD cell membrane mole-
cule, accounts for HIV's tropism and cytopathic effect (1). CD4, predominantly ex-
pressed on helper T lymphocytes but also on other cells, including macrophages
and monocytes, is considered asthe maincellular receptor for HIV (2, 3). The enve-
lope glycoprotein ofHIV is first synthesized asa 160-kD precursorthat islatercleaved
into external gp120 andtransmembrane gp41 (4). Thebindingsite toCD4is located
on gp120, while the region responsible for membrane fusion appears to be located
at the NH2 terminus of gp41 (5).
Carbohydrate moieties ofglycoproteins areknown toplay different roles in intra-
cellular routing (6), protection ofthe molecule against proteolytic degradation (7),
governing correct folding and stabilizing bioactive conformation ofthe molecule (7),
orasepitopes forantibody immune responses (8, 9). Carbohydrates are also involved
in the regulation ofmolecular metabolism (10-12), growth and differentiation (11,
13), and in cell-to-cell adhesion (14, 15).
Inviruses, carbohydrates have been implicated directly in the virusbiological ac-
tivity (16), or indirectly in the maintenance ofits tridimensional and quaternary
structure (16-18). They are also used by viruses as well as by parasites to escape the
immune defenses of the infected host (19).
Few, and sometimes contradictory, results have been reported regarding the car-
bohydrate composition of gp120 and its role in binding to CD4 (20-22), and even
less have been reported with respect to CD4.
Using different glycosidases, we have approached the carbohydrate composition
and optimal deglycosylation conditions of soluble recombinant gp160 and gp120,
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and of CD4. Binding assays of gp120 or of gp160 to radiolabeled soluble CD4 at
the molecular level and to CD4 receptor expressed at the cell membrane have al-
lowed us to examine whether deglycosylation of either molecule was of importance
for their interaction.
Materials and Methods
Soluble Recombinant gp120 and gp160.
￿
gp120 and gp160 were gifts from Transgene S. A.
(Strasbourg, France). Briefly, the eno-coding sequence ofgp120, in which a chain-terminating
codon was introduced to prevent the synthesis of gp41, was inserted in the thymidine-kinase
gene ofvaccinia virus (VV)' . Recombinant VVinfected BHK-21 cells produced gp120 that
was then easily released from the cell membrane. The molecule was purified by ammonium
sulfate and ethanol precipitation, followed by reverse phase HPLC. The gp160 precursor was
produced using a similar protocol. To prevent the subsequent cleavage ofthe precursor gp160
into gp120 and gp41, the potential coding sequence of the cleavage site was deleted (23).
Soluble CD4.
￿
Soluble recombinant CD4 (sCD4) was a gift from Dr. R. Axel (Columbia
University, New York, NY) (24-27).
Purification ofAnti-gpMOMurine Monoclonal (110-4).
￿
mAb 110-4 (Genetic Systems, Seattle,
WA) (28, 29) recognizes an epitope located at position 308-328 on gp120 of HIV-1 LAVBRU.
IgG were purified in one step by filtration of 1 ml of ascites fluid through a Sephadex G 200
column (Pharmacia Fine Chemicals, Uppsala, Sweden) (2 x 100 cm). Thereafter, 10 mg of
IgG was coupled to 4 g of CNBr Sepharose CL4B (Pharmacia Fine Chemicals) according
to the manufacturer's instructions.
Iodination of sCD4 and of gp160.
￿
10 pg of sCD4 in 50 Al of PBS pH 7 .4, and 0.25 mCi
of Na 1211 (13-17 mCi/p,g) (Amersham International, Amersham, UK) were added to 5 nmol
of an iodogen-coated tube and incubated for 10 min at room temperature. The reaction was
stopped by adding 10 Fcl of tyrosine at 9 mg/ml. The iodinated glycoprotein was desalted
from Na 1251 by filtration through a Sephadex G25 (PD 10) column (Pharmacia Fine Chem-
icals). Specific radioactivity of radiolabeled sCD4 (' 251-sCD4) was -5.5 uCi/j,g.
5 NAg of soluble gp160 were radiolabeled according to the same protocol. Specific radioac-
tivity of radiolabeled gp160 (1251-gp160) was there -36 pCi/pg.
Analytical Deglycosylation of .25I-gp160.
￿
This treatment was carried out under different con-
ditions: either I ng of 1251gpI60 (50,000 cpm) was incubated with different amounts of Endo
F commercial mixture (Endo F N-glycanase) (Boehringer Mannheim Biochemicals, FRG)
(2 x 102-2 x 10-2 mU) at 37°C for 24 h in 30 pl of 50 mM PBS, pH 7.4, with or without
1% (vol/vol) Triton X-100 (Sigma Chemical Co., St. Louis, MO) and 0.02% (wt/vol) SDS
(Bio-Rad Laboratories, Richmond, CA) or it was treated with different amounts of Endo
F N-glycanase free (Boehringer Mannheim Biochemicals) (2 x 102-2 x 10-2 mU) at pH 5.0
in 30 pl of 100 mM sodium acetate buffer with or without 1 % Triton X-100 and 0.02 % SDS.
Treatment with Clostridium perfringens neuraminidase (Sigma Chemical Co.) (50 mU), or
with Endo H (Boehringer Mannheim Biochemicals) (2 x 10- '-2 mU) was performed at pH
5.0 under similar conditions. Native or deglycosylated proteins were heated at 100°C for
3 min in the presence of 3% S-ME (Sigma Chemical Co.), and then submitted to 10% SDS-
PAGE according to Laemmli (30). Gels were exposed to Kodak x OMat film for 20 h.
Deglycosylation ofgp120 and gp160 Usedfor Binding Assays.
￿
Deglycosylation of gp160 and
of gp120 was performed as follows. 20 jag of the molecule was incubated in 120 pl of PBS,
pH 7 .4. Endo F N-glycanase (3 U) was sequentially added four times at 3-h intervals. After
digestion, aliquots of 1 jig of gp120 and of gp160 were analyzed by SDS-PAGE and Coomassie
staining. Moreover, radiolabeled 1251-gp160 was used in one experiment in order to deter-
mine by analytical electrophoresis the degree of deglycosylation obtained for this molecule
under these conditions (data not shown).
Analytical Deglycosylation of'25I-sCD4.
￿
Increasing amounts ofendoglycosidase (2 x 10- '-2
mU of Endo H; 2 x 10-2-2 x 102 mU of Endo F N-glycanase or Endo F) were added to
1 Abbreviation used in this paper: VV, vaccinia virus.FENOUILLET ET AL.
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7 ng of '2sI-sCD4 (50,000 cpm) in a final volume of 30 pl of previously described buffer in
the presence of Triton X-100 and 0.02% SDS. SDS-PAGE was then performed.
Preparative Deglycosylation of I25PsCD4forBindingAssays.
￿
Deglycosylated '"I-sCD4 was pre-
pared as follows. 100 p,l of '251-sCD4 (106 cpm) were incubated with 500 mU ofEndo F N-gly-
canase at pH 7 .4 under the same conditions as described above, with the exception that SDS
was omitted.
MolecularBindingAssays.
￿
To test the role ofCD4 carbohydrate moieties in the interaction
of this molecule with gp120 or gp160 (thereafter referred to as gp120/160), we compared the
binding capacity of glycosylated and deglycosylated'25I-sCD4 in the following test. 50,ul of
mAb 110-4 coupled to Sepharose CL4B (Pharmacia Fine Chemicals) (vol/vol) were incubated
with different amounts of gp 120/160 (0.5 ng to 500 ng) for 2 h at 4'C. Unbound soluble
gp120/160 was eliminated by two washes with 1 ml of PBS buffer, and a fixed amount of
glycosylated or deglycosylated '251-sCD4 (60,000 cpm) was added. The mixture was in-
cubated for 3 h at 4'C in order to prevent further deglycosylation by glycosidases. After two
washes, solid phase-bound radioactivity was counted in a gamma counter (Kontron Analyt-
ical, Zurich, Switzerland). The role of carbohydrate moieties of gp120/160 in its interaction
with CD4 was analyzed in the same assay but with deglycosylated gp120/160 bound to mAb
110-4 coupled to Sepharose CL4B.
CD4' Lymphoid Cells.
￿
Cells ofthe CEM line (American Type Culture Collection, Rock-
ville, MD) were cultured at 37'C in RPMI 1640 medium (Flow Laboratories, Inc., Irvine,
Scotland) supplemented with 10% FCS, 1% glutamine, and 1% antibiotics (Gibco Laborato-
ries, Paisley, Scotland) in a humidified atmosphere with 5olo C02.
BindingofNative or Deglycosylatedgp120/160to the CD4' Cells.
￿
Buffer solutions used in this
assay were those described by McDougal et al. (31). Different amounts of the native or
deglycosylated gp120/160 (0.25-250 ng) were incubated for 1 h at 37'C with 106 CEM cells
in 25 /Al of buffer. The cells were washed and resuspended in 25 Ftl of mAb 110-4 diluted
in buffer (1 :100). After 30 min at 4°C, they were washed, and incubated again for 30 min
at 4°C with 1 :25 sheep anti-mouse IgG coupledto biotin. After washing, cells were resuspended
in 25 pl of streptavidin-phycoerythrin (Becton Dickinson & Co., Mountain View, CA) (1 :25)
for 30 min at 4°C. After two more washes, cells were resuspended in 500 u1 of buffer con-
taining 1 17o paraformaldehyde. Membrane fluorescence intensity was measured by the FAGS
analyzer *(Becton Dickinson & Co.).
AssayfortheInhibition ofSyncitiumFormationbetween HIVinfected CEMCells andMoltT4 Cells.
104 CEM cells that were chronically infected with HIV-1 LAVBRU or HIV2ROD were cocul-
tured with 4 x 104 uninfected Molt T4 cells in wells (100 p,l) of 96-microtiter plates. Cells
were incubated for 18 h at 37°C in the presence ofdifferent concentrations (6.25-6,250 ng/ml)
of native or deglycosylated gp120. The number of syncitia was then counted. As a positive
control for the inhibition of cell fusion, the effect of 2.5,ug/ml of anti-Leu-3a (Becton Dick-
inson & Co.), an HIV-neutralizing anti-CD4 mAb (1), was determined in parallel in each
experiment.
Capacity ofNative or Deglycosylated gp120/160to Inhibit
125I- g p160 Bindingto CD4' Cells.
￿
5 x
106 CEM cells were incubated with 50 p.l (200,000 cpm) Of '2sI-gp160 (2 x 10-9 M) and 50,ul
of different concentrations (1.6 x 10-7-3 .1 x 10- '° M) of unlabeled native or deglycosylated
gp120/160. After 3 h at 37°C, cells were washed with 2 x 1 ml ofPBS buffer and radioactivity
of the pellet was determined in a gamma counter.
Results
Endoglycosidases are specific enzymes that cleave carbohydrates at their attach-
ment point on the glycoprotein amino acid skeleton, dependent on parameters such
as the accessibility of the internal N acetyl glucosamine, the nature of the glycans,
the enzyme concentration, and pH (32).
Deglycosylation of "5Igp160.
￿
To determine whether the accessibility of glycan
moieties of gp160 was important for the efficiency ofdeglycosylation, we tested different
conditions of enzymatic treatment. Treatment of gp160 with 0 .02% SDS and 1810
￿
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FIGURE 1 . SDS PAGE and autoradiography of 121I-gp160 after neuraminidase or Endo F
N-glycanase treatment. Lane 1, Overnight incubation at pH 7.4 as control. Lane 2, 50 mU of
neuraminidase. Lanes 3-7, 2 x 10- 2-2 x 102 mU of Endo F N-glycanase in the absence of SDS
and Triton X-100. Lanes 8-12, 2 x 10-2-2 x 10 2 mU of Endo F N-glycanase in the presence
of 0.02% SDS and 1% Triton X-100 .
Triton X-100, or by heating at 100°C for 3 min before incubation (data not shown),
did not change the end result of the procedure ; accessibility of glycans to the en-
zymes was identicalwhether themolecule had been denatured or not (Figs. 1 and 2) .
Endo F N-glycanase, which comprises EndoF and contaminantN-glycanase(33),
cleaves all glycan species from the molecule (34, 35) ; complete deglycosylation was
obtained with 200 mU of enzymes, leading to the decrease of the molecular mass
of the deglycosylated molecule from 160 to 90 kD (Fig. 1) .
Endo F cleaves most of the high mannose, hybrid type glycans, and biantennary
species (32, 34) . Deglycosylation ofgp160 by 200mU ofEndo Fdecreased its molec-
ular mass to 130 kD (Fig. 2) .
FIGURE 2 .
￿
SDS-PAGE and autoradiography of 12'I-gp160 after Endo H or Endo F treatment .
Lanes 1 and 2, incubation at pH 7.4 (1) or 5 (2) as controls. Lanes 3-7, 2 x 10-4-2 mU ofEndo
H in the absence of SDS and Triton X-100 . Lanes 8-12, 2 x 10-'-2mU of Endo H in the pres-
ence of 0.02% SDS and 1% Triton X-100 . Lanes 13-18, 2 x 10-2-2 x 10 2 mU of Endo F in
the absence of SDS and Triton X-100 . Lanes 19-22, 2 x 10-2-2 x 102mU of Endo F in the
presence of 0.02% SDS and 1% Triton X-100 .FENOUILLET ET AL.
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EndoH cleaves most of the high mannose species (32) . Here again, deglycosyla-
tion of gp160by thisenzyme (2 mU) decreased itsmolecular mass to 130kD (Fig . 2) .
Desialylation by neuraminidase, which removes sialic acid molecules, decreased
the molecular mass of gp 160 to 130 kD (Fig . 1) .
To compare and characterize the efficiency of the deglycosylation of gp160 and
gp120 used for the binding assays, SDS-PAGE analysis of these molecules was per-
formed before and afterenzymatic treatment . Native gp160 and its radioactive coun-
terpart had similar characteristics (data not shown) . Treatment of gp120 with Endo
H, Endo F N-glycanase, and Endo F resulted in decreases of molecular mass in the
same proportions as for gp160 (Fig . 3) . Lower molecular mass bands are enzymes
(65 and 72 kD) (Fig . 3, lane 2, for example) .
Deglycosylation of 1251-sCD4.
￿
To rule out the hypothetical influence of glycan ac-
FIGURE 3 .
￿
SDS-PAGE of gpl20 and of 1251-sCD4 used in the binding assays after treatment
with different glycosidases . Lane 1, gpl20 incubated overnight at pH 7.4 as control . Lane 2, 1 Wg
of gpl20 treated with neuraminidase (500 mU). Lane 3, 1 jig ofgp120 treated with Endo H (20
mU) in the absence of SDS and Triton X-100 . Lane 4, 20 jig of gp120 incubated with Endo F
N-glycanase as used in binding assays (1 Wg aliquot). Lane 5, deglycosylated 1251-sCD4 used in
the binding assay (absence of SDS) . Lane 6, 1251-sCD4 incubated overnight at pH 7.4 as control .81 2
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cessibility to the enzymes, we first compared the degree of deglycosylation obtained
under denaturing in the presence of SDS or nondenaturing conditions (data not
shown) . Results obtained under both conditions were similar.
5 mU ofEndo H, as well as 200 mU ofEndo F, failed to deglycosylate 7 ng of
sCD4 (Fig . 4), whereas Endo F N-glycanase at pH 7.4 deglycosylated sCD4 to the
same extent whether in the presence (Fig. 4) or in the absence (Fig. 3) of SDS.
Three forms of the molecule appeared when using 2 x 10 -1 mU ofEndo FN-gly-
canase : glycosylated CD4 (50 kD); CD4 with one glycan chain (48 kD); and totally
deglycosylated CD4 (46 kD) (Fig. 4) . The use of 2 mU ofEndo F N-glycanase at
pH 7.4 led to a unique homogeneous deglycosylated form of the molecule of 46 kD
(Fig . 4), a shift in molecular mass that could be accounted for by the removal of
two glycan chains . When evaluated in the presence of Triton X-100 and in the ab-
sence of SIDS, deglycosylation of sCD4 used for binding assays was also found to
be complete (Fig . 3) .
Bindingof"I-sCD4 to gp120/160 .
￿
mAb 110-4 recognizes an epitope located be-
tween amino acid 308 and 328 of gp120 of the LAVBRU isolate ofHIV1 . Although
this mAb significantly inhibits the binding ofHIV -1 to CD4+ cells and even neu-
tralizes virus infectivity, it recognizes soluble gp120 already complexed to CD4+ cells
andonly reducesby twofoldthe avidity of gp120binding to CD4 (28, 29) . This indi-
cates that the epitope recognized by mAb 110-4 is not involved in the binding site
of gp120 to CD4. We took advantage of this characteristic to set up a quantitative
assayto measurebindingofsCD4 to thebeads . mAb 110-4 was coupled to Sepharose
CL4B beads and then complexed with native gp120/160 ; '21j-sCD4 was added and
allowed to bind to gp120/160 . 1251-sCD4 fixed to gp120/160-mAb 110-4-Sepharose
FIGURE 4 .
￿
SDS PAGE and autoradiography of 1251-sCD4 after Endo F N-glycanase, or Endo
For EndoH treatment . Lanes1 and 3, overnight incubation at pH 5 (1) or 7.4 (3) as controls .
In all other lanes, 1251-sCD4 was treated in the presence of 0.02% SDS and 1% Triton X-100 .
Lane 2, EndoH(5mU) ; Lanes 4 to 8, pure Endo F (2 x 10-2-2 x 102mU); Lanes 9-13, Endo F
N-glycanase (2 x 10-2-2 x 10 2 MU).6
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complexes was separated from theunbound molecule by centrifugation. Fig. 5 shows
that binding of 1251-sCD4 increased with the amount of native gp160 that was used
in this assay, and similar results were obtained when gp120 was used in the assay
(Fig. 6). 1251-sCD4 binding was specific because it was proportional to the concen-
tration of gp120/160 used, and no binding was obtained when the same amount of
gp160 wasincubatedwith N-acetyl glucosamine coupled to Sepharose instead ofmAb
110-4 (data not shown).
CarbohydratesofsCD4Are notNecessaryforBinding toNativegp120/160.
￿
Preliminary
experiments had shown that 0.02% SDS abolished the specific bindingof 1251-sCD4
to gp120/160 (results not shown). Therefore, because total deglycosylation of sCD4
with Endo F N-glycanase at pH 7.4 could also be obtained in the absence of SDS,
we used only 1% Triton X-100 in all the experiments. Results of Fig. 5 clearly show
that deglycosylated (see Fig. 3) and native 1251-sCD4 bound to native gp160 with
a similar avidity; the apparent decrease of the binding capacity of deglycosylated
1251-sCD4 is due only to the effect ofTriton X-100 since the same decrease ofbinding
of glycosylated 1251-sCD4 was obtained in the presence of a similar concentration
of Triton X-100.
Role ofthe Carbohydrate Moieties ofgp120/160 in the Binding to sCD4.
￿
Preliminary
experimentshad shownthat gp120/160 fixedto mAb-110-4-Sepharose complexes could
Dose of gp (ng)
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FIGURE 5.
￿
Effect of deglycosyla-
tion of 1251-sCD4 on thebindingto
gp160. After incubation of mAb
110-4-SepharoseCL4B with gp160
(0.5-500 ng), 50,000 cpmofnative
(CD4) or deglycosylated (dCD4),
or Triton X-100-treated native
1251-sCD4 (CD4 + Triton) were
added for2h. Boundradioactivity
was counted.
FIGURE 6.
￿
Effect ofdeglycosylation of
gp120/160 on the binding of sCD4.
Afterincubation ofmAb 110-4-Sepha-
rose CL4B with native (gp120-gp160)
or deglycosylated (dgpl20-dgp160) gly-
coproteins (0.5-500 ng), 50,000 cpm
of 1251-sCD4 were added for 2 h.
Bound radiography was counted.814
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stillbind to sCD4. It was thus important to demonstratethat deglycosylated gp120/160
continued to bind to 110-4 mAb-Sepharose to the same extent as native gp120/160.
As expected, complete deglycosylation of 1251-gp160 did not change its immunoreac-
tivity to mAb 110-4 (Table 1).
In the molecular assay used, 1251-sCD4 could still bind to deglycosylated
gp120/160 in a dose-dependent manner that was proportional to the amount of
gp120/160 used (0.5-500 ng) (Fig. 6). However, binding capacity of 1251-sCD4 to
deglycosylated gp120 and gp160 was reduced by two- to fivefold as compared with
the respectively native molecules.
Binding ofNative andDeglycosylated gp120/160 to the Membrane CD4 of CEMLymphoid
Cells. To further investigate the influence of carbohydrate moieties of gp120/160
in the interaction with CD4, we compared the capacity of native and deglycosylated
gp120/160 to bind to CD4+ cells of the CEM line in an indirect immunofluores-
cence assay. Different amounts of native or deglycosylated gp120/160 (0.25-250 ng)
were incubated with 106 cells and the amount of gpl20/160 bound to the cells was
determined by the fluorescence intensity obtained after labeling with mAb 110-4.
Results of these experiments (Fig. 7) clearly show that deglycosylation of gp120 or
gp160 did not abolish their binding capacity to CD4+ cells, but here again, the
bindingcapacity ofthe deglycosylated gp120and gp160was reducedfour to sixtimes,
as compared with the respectively native molecules.
Native and Deglycosylated gp120 Inhibit to the Same Extent Syncytium Formation between
HIVinfected and Uninfected CEM Cells. Native and deglycosylated gp120 were tested
for theircapacity to inhibit formation of syncitia between HIV1- or HIV2-infected
CEM cells and fresh uninfected Molt T4 cells. Complete inhibition of syncitium
formation by native gp120 was noted with 0.62 Ag/ml for HIVl-infected cells, with
6.25 lcg/ml forHIV2-infected cells (Fig. 8) and when cellswere incubated with Leu-
3a (2 .5 ug/ml), an anti-CD4 antibody. Resultsin the same rangewere obtained with
deglycosylated gpl20. Thus, despite the absence of carbohydrate chains, the
deglycosylated molecule neutralizes cell fusion between HIVinfected and uninfected
CD4+ cells with the same efficiency as the native molecule.
Affinity ofthe Binding ofNative andDeglycosylatedgp120/160 to CEMCells.
￿
Theaffinity
for the CD4 receptor of native gp120 and gp160 and of deglycosylated gp120 was
measured in competition experiments of native vs. 1251-gp160 molecules for the
binding to CD4+ cells. Fig. 9 shows the 1251-gp160 binding curve to CEM cells in
the presence of increased concentrations of native and deglycosylated gp120 (1 .6 x
10 -1-3.1 x 10 -1o M); the Ko.5, i.e., the concentration of native molecule required to
reduced by 50% 1251-gp160 binding, was four times higher for deglycosylated (5 x
TABLE I
Fixation of Native (g¢) or ofDeglycosylated (dgp) gp160 (50, 000 cpm)
to 110-4 Sepharose CL4B (50,al)
Exp.
￿
Bound gp
￿
Bound dgp
cpm
1
￿
13,344
￿
14,015
2
￿
14,816
￿
13,531FENOUILLET ET AL.
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￿
Inhibition of syn-
citium formationbetween HIV
infected andnoninfected CD4'
cells. Chronically infected CEM
cellswith HIVI (A)or HIV2 (B)
were cocultured with freshMolt
T4 cells. Syncitia were counted
after 18 h. Inhibition of syn-
citium formationby increasing
amounts of native (gp120) or
deglycosylated (dgpl20) glyco
$ gp120
￿
protein in culturemedium was
+ dgp120
￿
observed and expressed by ref-
erence to 100% ; i.e., thenumber
of syncitia in the absence of
gp120 in the medium.
10 -8 M) than for native gp120 (1.25 x 10-8 M). The method of Muller (36) enables
us to calculate a dissociation constant by using the formula Kd = 3/8 (1-T), where
T = (125I_gp160) = 2.10-9 M; I = Ko.s = 1.25 x 10-8 M for native gp120 and
5 x 10-
8 M for deglycosylated gp120). Applying this formula generated Kd = 4.7
x 10-9 M for native gp120 and 18 x 10 -9 M for deglycosylated gp120 . These Kd
FIGURE 9.
￿
Affinity of the bindingofna-
tive gp120andgp160andofdeglycosylated
gp120to CEM cells. 106 CEM cells were
incubated overnight with 121I-gp160 and
different concentrations ofgp120(gp120),
gp160 (gpl60), or deglycosylated gp120
(dgp120). 121I-gp160 bound to cells was
then counted.FENOUILLET ET AL.
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values demonstrate that the presence of carbohydrate chains is not a major factor
forgp120bindingwith high affinity to CD4 molecules expressed at the cell membrane.
Discussion
The objective of this study was to analyze the glycan moieties of gp120/160 and
of sCD4 and to further examine whether carbohydrates of either molecule played
a significant role in the interaction between HIV and CD4+ cells since, up to now,
contradictory results have been reported at least with respect to gp120/160 (20-22).
To evaluate this role at the molecular level, we needed efficient and reliable methods
that totally deglycosylated the two molecules involved without denaturing or pro-
teolyzingtheir peptide backbones. This led us first to examine, with different glycosi-
dases, the accessibility of carbohydrate chains and their composition owing to en-
zyme specificity.
sCD4, which possesses two glycosylation sites (37), was produced in mammalian
cells, and so itsglycosylation was supposedly close to what it is normally. Deglycosy-
lation ofsCD4 resulted in a 4-kD shift ofthe initial molecularmass that corresponded
well with the removal of two glycans of 2 kD each. 2 kD is indeed the approximate
molecularmass of a triantennary chain composed of 10-12 residues of -200 daltons
each, or of a high mannose type that also comprises 10 residues (38). These two
carbohydrate moieties were easily removed only by Endo F N-glycanase at pH 7.4,
a condition under which N-glycanase is also active in addition to Endo F (33-35).
Thus, glycans of CD4 are probably either of triantennary structure, or they may
represent some rare fucosylated hybrid or high mannose structures that are usually
resistant to pure Endo F or Endo H activity (32-35). These results also suggest the
homogeneity of the glycosylation of the sCD4 used here, because all the molecules
were similarly sensitive to N-glycanase activity. This is surprising in regard to the
well known glycan heterogeneity (38). That removal of N-linked glycans was pos-
sible in the absence of SDS can be interpreted as resulting from the good accessi-
bility to theenzymesof glycan moieties on thenative folded CD4 molecule; moreover,
these conditions of deglycosylation (in the absence of SDS) allowed us to obtain a
deglycosylated form of sCD4 that was active in binding assays to gp120/160.
Deglycosylation ofsCD4 did not reduce itsabilityto bind to gp120/160. This clearly
demonstrates that carbohydrate moieties of CD4 are not essential for the binding
to gp120 andconfirms otherobservations that cells expressing CD4that lacksN-linked
glycosylation sites can be infected by HIV (37). This finding is in line with the re-
cent observation that glycosylation sitesare locatedon the third and fourth domains
of CD4, while only the first Ig-like domain of CD4, which lacks N-linked glycans,
appearsto be directly involved in the receptor function for HIV (27, 39). This, how-
ever, cannot rule out the possible role of CD4 carbohydrate moieties in the interac-
tion with its natural ligands such as HLA class II molecules for example (40).
Treatment of gp120/160 by Endo F and by Endo H yielded a partial degree of
deglycosylation that was similar with both enzymes, indicating that approximately
half of the glycans ofthemolecule are sensitive to these enzymes. The carbohydrate
moieties cleaved maythen be ofthe high mannose type possibly associated with some
hybrid or biantennary species (32, 33). Other glycans, cleaved only by N-glycanase
activity at pH 7.4, are probably of particular high mannose or biantennary chains
that are not sensitive to Endo H and Endo F activity, or they may be triantennary818
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species (33-35). This confirms and expands recent findings reported by others (41).
As for CD4, the total removal of carbohydrates from gp120/160 in the absence of
SDS indicates that their attachment point is accessible on the molecule in its native
conformation.
Sialic acid content of gp160 appears to be quite important, since treatment with
neuraminidase resulted in the loss of -30 kD of its apparent molecular mass. This
is in agreement with results previously reported by McDougal et al. (42), and it
may correspond to high sialylation of carbohydrate chains; however, this shift is in
apparent contradiction with theelevated number ofhigh mannose type species that
are removed by Endo F or Endo H. The maximum sialylation oftriantennary chains
is normally associated with a sialic acid content of -20% of the carbohydrates (37).
However, as determined by enzymatic deglycosylation, no more than half of glycan
moieties ofgp120/160 are able to be sialylated (biantennary or triantennary chains).
Therefore, desialylation of gp 120/160 should not result in a shift more important
than 10% of the molecular mass, i.e., 10-15 kD. The shift obtained here may then
be due to polysialic series branched at the periphery of the chains.
There has been considerable speculation (20-22, 43) as to the role of carbohy-
drates moieties of gpl20, whose glycosylation sites are highly conserved (44), in the
interaction with CD4. The molecules used in the present study were completely
deglycosylated as indicated by the reduction in molecularmass, observed with auto-
radiography or Coomassie staining after SDS-PAGE, which was in the same range
as what has been previously reported by otherauthors(20). Additional proofdemon-
strating that the gp120 andgp160 used in the bindingassays were fullydeglycosylated
was obtained by HPLC analysis on a Biosyl TSK 250 column (Bio-Rad Laborato-
ries) that confirmed the lack of detectable glycosylated contaminant in the prepara-
tions used and the exclusive presence of homogeneous deglycosylated form of the
molecules. Moreover, gasliquid chromatography ofthe deglycosylated preparations
was performed after purification on a Cl column ; here again, contamination by
glycosylated molecule wasundetectable (<3-5%) (B. Fournet, O. Koll, andJ. Mon-
treuil, personal communication).
Thus, our results clearly indicate that completely deglycosylated gp120 or gp160
can still bind to the CD4 receptor, either in a soluble form or expressed at the cell
membrane, with a capacity that is only slightly reduced by two- to sixfold. In addi-
tion, fixation of 125I-gp160 (2 x 10-9 M) to CD4* cells is totally inhibited by native
as well as by deglycosylated gp120, although the 50% inhibition concentration (Ko.5)
is four times higher with the deglycosylated form (K o.5 = 5 x 10 -a M) than with
the native form of the molecule (Ko.5 = 1.25 x 10-8 M).
Taken together, the results presentedhere demonstrate that deglycosylated recom-
binant soluble gp120/160 retains the structural and biological properties of the na-
tive viral glycoprotein, binds with high affinity to CD4' cells (K, 18 nM) and in-
hibits syncytium formation mediated by HIVI- or HIV2-infected cells within the
same range ofefficiency as the native molecule. This indicatesthat the carbohydrate
chains of gp120 do not play a significant role in its interaction with CD4. However,
onecannot excludethat such limited reduction in theaffinity ofdeglycosylated gp120
to bind to its CD4 cellular receptor does not significantly impair the infectivity and
cytopathologyofnonglycosylated viralparticles. Moreover, it appearsthat antibodies
can neutralize HIVinfectivity in vitro by interfering only to such extent with gp120-FENOUILLET ET AL.
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CD4 interaction. Nevertheless, our findings are in apparent contradiction with re-
cent reports from other authors (20-22). The drastic decrease of the binding ca-
pacity to CD4 ofcompletely deglycosylated gp120, obtained by Matthews et al. (20)
might then not be due only to the removal of carbohydrates per se, as suggested,
but it may be rather related with conformational factors due to changes within the
structure ofthe molecule in relation with the use of denaturing agents such as SDS.
In our hands, for example, the use of 0.02% SDS in deglycosylation procedures of
gp160 -diminished its binding to CD4 by 20 times (data not shown).
On theotherhand, the fact that native and deglycosylated gp120 inhibit syncitium
formation between HIVinfected and noninfected CD4+ cells in the same range
argues against the interpretation brought by Gruters et al. (22) that it is the ab-
normal glycosylation of viral glycoproteins generated by the treatment of cultured
HIV-infected cellswith castanospermine and deoxynojirimycin (which both inhibit
oligosaccharide processing) that renders the virus unable to efficiently infect these
cells and to induce syncitium formation because of the lack of binding of abnor-
mally glycosylated gp to CD4. Similarly, results of syncitium inhibition by lectin
(Con A) reported by Lifson et al. (43) could be explained by steric hindrance, as
suggested by the authors rather than by the direct involvement of carbohydrate moi-
eties in gp120-CD4 interaction.
Alternatively, it cannot be excluded that carbohydrates of gp120/160 play a role
in a hypothetical secondary interaction of gp120/160 with themembrane. The func-
tion of carbohydrates has been investigated in the case of glycoprotein hormones.
Forexample, specific deglycosylation ofluteinizing hormoneleads to a molecule that
has an increased capacity to bind to its cellular receptor but that has a significantly
diminished ability to stimulate adenylate cyclase activity. It has been proposed in
this case that sugars are required for transduction of the hormone signal into the
cells (45).
Based on these facts (20-22), one can hypothesize that N-linked carbohydrates
of HIV gp120/160 may play a role in the folding ofthe protein or in its stabilisation.
However, a major and direct role of glycan moieties in gp120/160-CD4 interaction
canbe excluded. Experiments with gp120/160obtained by cloning in procaryote cells
will be necessary, as will be thedesign of a synthetic conformational peptide including
the binding site to CD4 receptor that could be made for the development of a syn-
thetic vaccine in order to test this hypothesis.
Summary
gp120 and CD4 are two glycoproteins that are considered to interact together to
allow the binding of HIV to CD4+ cells. We have utilized enzymatic digestion by
endoglycosidases in orderto analyze N-linked carbohydrate chains oftheseproteins
andtheirpossible role in the interaction of gp120or gp160with CD4. SDSdenatura-
tion was not necessary to obtain optimal deglycosylation of either molecule, but
deglycosylation ofCD4, nonetheless, depended on the presence of 1% Triton X-100.
Endo H and Endo F that cleave high mannosetype andbiantennary glycans diminish
the molecular mass of the glycoproteins from 120 or 160 Kd to 90 or 130 Kd, respec-
tively; but these enzymes had no action on CD4 glycans. Endo F N-glycanase mix-
ture, which acts on allglycan species, includingbiantennary chains, led to complete
deglycosylation of gp120/160 and of CD4. Therefore, probably half of the glycan820
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moieties of gp120/160 are composed of high mannose and biantennary chains, the
other half being triantennary species. The carbohydrate structures of CD4 seems
to be triantennary chains. To analyze the binding of gp120/160 to CD4, we used
a molecular assay in which an mAb (110-4) coupled to Sepharose CL4B allowed the
attachment of soluble gp120/160 to the beads; 1251-sCD4 was then added to mea-
sure the binding of CD4 to different amounts of gp120/160. Binding to gp160 was
not modified when using completely deglycosylated 1251-sCD4, while deglycosyla-
tion of gp120 or of gp160 resulted in the decrease of the binding to native CD4 by
two- and fivefold, respectively. Native and deglycosylated gP120/160 bound to CD4+
cells with comparable affinities. In addition, deglycosylated gp120 displaced 1251-
gp160 binding to CD4+ cells and inhibited fusion of fresh MoltT4 cells with CEM
HIV1- or HIV2-infected cells to the same extent. Taken together, these results indi-
cate that carbohydrates of CD4 and of gp120/160 do not play a significant role in
the in vitro interaction between these two molecules .
We are grateful to Mrs. Nathalie Charbonneau for preparation of the manuscript.
Receivedfor publication 17 November 1988.
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